| Price and Chart delayed at least 15 mintues. |
|
Price
$ 54.75
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
54.75
|
Volume
NA
|
|
Market Value
15 bil
|
P/E Ratio
32.6
|
|
Bid
54.58
|
EPS
1.68
|
|
Ask
54.76
|
Dividend
0.00
|
|
High
0.00
|
Yield
0.0
|
|
Low
0.00
|
Shares Out
270 mil
|
|
52wk High
83.97
|
52wk Low
50.05
|
|
Industry: Biotechnology
|
|
Sector: Healthcare
|
GENZ Profile
A global biotechnology company dedicated to making a major impact on the lives of people with serious diseases.
Genzyme Corp.
500 Kendall Street
Cambridge, MA 02142
Phone: (617) 252-7500
Fax: (617) 252-7600
Web Site: www.genzyme.com
GENZ Wires Headlines
|
|
| 06.25.09 |
|
Genzyme confident Allston plant on line late July
|
|
| 06.25.09 |
|
UPDATE 1-Europe prepares for shortages of Genzyme drugs
|
|
| 06.25.09 |
|
BRIEF-EU body recommends priority release for Genzyme drugs
|
|
| 06.22.09 |
|
A year on, Mass. life sciences act fuels research
|
|
| 06.21.09 |
|
A year on, Mass. life sciences act fuels research
|
More GENZ From Wires Headlines >
Forbes.com on GENZ RSS
|
|
|
Genzyme is ranked # 881 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on GENZ
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on GENZ
RSS News Feed on GENZ
|
A D V E R T I S E M E N T
|